TERUMO Japan | 中文 | Size Small Big
Terumo Announces Strategic Alliance with Chinese AngioCare

 Tokyo ― Terumo Corporation (TSE: 4543 Section 1) today announced that a strategicalliance has been formed with Shanghai AngioCare Medical Technology Co., Ltd.(hereinafter “AngioCare”) (Representative: Philip Wang), a Chinese company in renal denervation technology for resistant hypertension treatment. Terumo will take on a 20% share in AngioCare. Furthermore, Terumo will consign product development to AngioCare and acquire the exclusive distribution rights for its renal denervation technology on the global market.

 1. Renal denervation


  The renal sympathetic nerve plexus is a major contributor of hypertension. During renal denervation, a catheter is introduced using standard interventional technique via the femoral artery, and is positioned in the renal artery under fluoroscopic guidance. The electrode at the distal tip of the catheter delivers high radio frequency through the wall of renal artery to ablate or disrupt the surrounding renal sympathetic nerves lying in the vessel. Renal denervation using a catheter-based technique is highly expected to be a new, effective treatment option for the many patients with hypertension who do not respond to conventional drugs, or “resistant hypertension”. In China, approximately 230 million people are currently suffering from hypertension. Among them, 5.4 million are candidates for renal denervation and the number of such patients is expected to reach approximately 7.2 million by 2025.


2. Objectives of alliance


 Terumo has formulated key strategic themes of further promoting business localization and partnership with local companies in China. The alliance in this press release is a part of the mentioned key strategic themes. By entering Chinese renal denervation market with the first domestically manufactured product, Terumo aims for further expansion of its Chinese interventional systems business which offers great future opportunity. Terumo expects it will start sales of its renal denervation system in fiscal year 2015 and aims to achieve around 20% of share in Chinese market, which size is expected to reach over 50 billion yen by year 2020. As for sales outside China, Terumo will conduct a further examination of the opportunity.The mentioned alliance is not expected to have an impact on business results for the current fiscal year.

3. Outline of alliance